MENLO PARK, Calif.--(BUSINESS WIRE)--SRI International, an independent nonprofit research and development organization, today announced it has signed an agreement with Taiwan Liposome Company (TLC), a biopharmaceutical company, to begin preclinical safety and toxicology studies of a new cancer drug developed by TLC. The studies will be conducted in support of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).
